GSK 4528287
Alternative Names: GSK-4528287Latest Information Update: 10 Feb 2025
Price :
$50 *
At a glance
- Originator GSK
- Class Anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Crohn's disease; Ulcerative colitis
Most Recent Events
- 18 Nov 2024 Phase-I clinical trials in Crohn's disease (In volunteers) in United Kingdom (unspecified route) (NCT06681181)
- 18 Nov 2024 Phase-I clinical trials in Ulcerative colitis (In volunteers) in United Kingdom (unspecified route) (NCT06681181)
- 08 Nov 2024 Preclinical trials in Crohn's disease in United Kingdom (unspecified route) prior to November 2024